3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
5
Phase 1/2
3
Phase 3
2
Phase 2/3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
2
Interventions
Rituximab
49
Cyclophosphamide
28
venetoclax
24
Bendamustine Hydrochloride
24
obinutuzumab
22
ibrutinib
21
Chlorambucil
20
fludarabine
16
fludarabine phosphate
15
idelalisib
13
acalabrutinib
11
pirtobrutinib
7
ofatumumab
7
zanubrutinib
5
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Cyclosporine
5
Radiotherapy
4
Prednisone
4
Doxorubicin
4
duvelisib
3
Whole-Body Irradiation
3
Specimen Handling
3
Methotrexate
3
Lenalidomide
3
Filgrastim
3
Epoetin Alfa
3
Cyclosporins
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
ublituximab
×
Clear all
NCT02612311
2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3
Terminated
603 enrolled
17 charts
NCT02301156
2022-05-20
GENUINE
TG Therapeutics, Inc.
Phase 3
Completed
126 enrolled
18 charts